Psychopharmacology

, Volume 188, Issue 3, pp 386–392 | Cite as

Lamotrigine inhibits basal and Na+-stimulated, but not Ca2+-stimulated, release of corticotropin-releasing hormone from the rat hypothalamus

  • Giuseppe Tringali
  • Jean Michel Aubry
  • Pierluigi Navarra
  • Giacomo Pozzoli
Original Investigation
First Online:
Received:
Accepted:

Abstract

Rationale

Corticotropin-releasing hormone (CRH) is a peptide neurotransmitter involved in the pathogenesis of anxiety and depressive disorders; CRH receptor antagonists are currently developed as anxiolytic and antidepressive agents, and several antidepressants negatively modulate CRH in the central nervous system.

Objectives and methods

Originally marketed as an antiepileptic drug, lamotrigine (LTG) was subsequently shown to be effective as a mood stabilizer and an antidepressant. In this study, we used acute rat hypothalamic explants to investigate the effects of LTG on the gene expression and secretion of CRH from the hypothalamus in short-term incubation experiments.

Results

We found that LTG reduces basal CRH release in a time- and concentration-dependent manner. LTG also inhibits veratridine-stimulated, but not K+-stimulated, CRH release in 1-h experiments. Moreover, LTG tended to reduce CRH mRNA expression in 1-h experiments, regardless of whether the drug was given alone or in combination with veratridine or high K+ concentrations; such reduction achieved statistical significance after 3 h of incubation.

Conclusion

In 1-h experiments, LTG reduces CRH release from CRH-containing neurons in the rat hypothalamus by interfering with Na+-driven secretion mechanisms. After 3-h incubations, the reduction in CRH release is also accounted for by LTG-induced decrease in CRH gene expression.

Keywords

Lamotrigine Veratridine CRH Hypothalamus Rat 
This is a preview of subscription content, log in to check access.

References

  1. Ahmad S, Fowler LJ, Whitton PS (2004) Effect of acute and chronic lamotrigine on basal and stimulated extracellular 5-hydroxytryptamine and dopamine in the hippocampus of the freely moving rat. Br J Pharmacol 142:136–142PubMedCrossRefGoogle Scholar
  2. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, Montgomery P, Earl N, Smoot TM, DeVeaugh-Geiss J (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 60:392–400PubMedCrossRefGoogle Scholar
  3. Bowden CL, Karren NU (2006) Anticonvulsants in bipolar disorders. Aust N Z J Psychiatry 40:386–393PubMedCrossRefGoogle Scholar
  4. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD (1999) A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 60:79–88PubMedGoogle Scholar
  5. Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, Kusumakar V, Ascher JA, Earl NL, Greene PL, Monaghan ET (2000) A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 61:841–850PubMedGoogle Scholar
  6. Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, Montgomery P, Ascher J, Paska W, Earl N, DeVeaugh-Geiss J (2003) A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 64:1013–1024PubMedCrossRefGoogle Scholar
  7. Castel-Branco MM, Falcao AC, Figueiredo IV, Caramona MM (2005) Lamotrigine pharmacokinetic/pharmacodynamic modelling in rats. Fundam Clin Pharmacol 19:669–675PubMedCrossRefGoogle Scholar
  8. Cheung H, Kamp D, Harris E (1992) An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res 13:107–112PubMedCrossRefGoogle Scholar
  9. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction. Anal Biochem 162:156–159PubMedCrossRefGoogle Scholar
  10. De Bellis MD, Gold PW, Geracioti TD Jr, Listwak SJ, Kling MA (1993) Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry 150:656–657PubMedGoogle Scholar
  11. Deffois A, Fage D, Carter C (1996) Inhibition of synaptosomal veratridine-induced sodium influx by antidepressants and neuroleptics used in chronic pain. Neurosci Lett 220:117–120PubMedCrossRefGoogle Scholar
  12. Fabricio AS, Tringali G, Pozzoli G, Navarra P (2005) Mirtazapine acutely inhibits basal and K(+)-stimulated release of corticotropin-releasing hormone from the rat hypothalamus via a non-genomic mechanism. Psychopharmacology 178:78–82PubMedCrossRefGoogle Scholar
  13. Grossman A, Costa A, Navarra P, Tsagarakis S (1993) The regulation of hypothalamic corticotropin-releasing factor release: in vitro studies. Ciba Found Symp 172:129–143PubMedGoogle Scholar
  14. Holsboer F, Barden N (1996) Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 17:187–205PubMedCrossRefGoogle Scholar
  15. Husum H, Van Kammen D, Termeer E, Bolwig G, Mathe A (2003) Topiramate normalizes hippocampal NPY-LI in flinders sensitive line ‘depressed’ rats and upregulates NPY, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects. Neuropsychopharmacology 28:1292–1299PubMedCrossRefGoogle Scholar
  16. Kehne J, De Lombaert S (2002) Non-peptidic CRF1 receptor antagonists for the treatment of anxiety, depression and stress disorders. Curr Drug Targets CNS Neurol Disord 1:467–493PubMedCrossRefGoogle Scholar
  17. Kling MA, Gardner DL, Calogero AE, Coppola R, Trettau J, Kellner CH, Lefter L, Hart MJ, Cowdry RW, Post RM et al (1994) Effects of local anesthetics on experiential, physiologic and endocrine measures in healthy humans and on rat hypothalamic corticotropin-releasing hormone release in vitro: clinical and psychobioogic implications. J Pharmacol Exp Ther 268:1548–1564PubMedGoogle Scholar
  18. Kunzel HE, Zobel AW, Nickel T, Ackl N, Uhr M, Sonntag A, Ising M, Holsboer F (2003) Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. J Psychiatr Res 37:525–533PubMedCrossRefGoogle Scholar
  19. Kuo CC (1998) A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na+ channels. Mol Pharmacol 54:712–721PubMedGoogle Scholar
  20. Kuo CC, Lu L (1997) Characterization of lamotrigine inhibition of Na+ channels in rat hippocampal neurones. Br J Pharmacol 121:1231–1238PubMedCrossRefGoogle Scholar
  21. Leach MJ, Marden CM, Miller AA (1986) Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 27:490–497PubMedCrossRefGoogle Scholar
  22. Lingamaneni R, Hemmings HC Jr (1999) Effects of anticonvulsants on veratridine- and KCl-evoked glutamate release from rat cortical synaptosomes. Neurosci Lett 276:127–130PubMedCrossRefGoogle Scholar
  23. McElroy SL, Zarate CA, Cookson J, Suppes T, Huffman RF, Greene P, Ascher J (2004) A 52-week, open-label continuation study of lamotrigine in the treatment of bipolar depression. J Clin Psychiatry 65:204–210PubMedCrossRefGoogle Scholar
  24. Meldrum BS (1991) Excitatory amino acid transmitters in epilepsy. Epilepsia 32(Suppl 2):S1–S3PubMedCrossRefGoogle Scholar
  25. Modell S, Yassouridis A, Huber J, Holsboer F (1997) Corticosteroid receptor function is decreased in depressed patients. Neuroendocrinology 65:216–222PubMedCrossRefGoogle Scholar
  26. Müller MB, Wurst W (2004) Getting closer to affective disorders: the role of CRH receptor systems. Trends Mol Med 10:409–415PubMedCrossRefGoogle Scholar
  27. Navarra P, Tsagarakis S, Faria MS, Rees LH, Besser GM, Grossman AB (1991) Interleukins-1 and -6 stimulate the release of corticotropin-releasing hormone-41 from rat hypothalamus in vitro via the eicosanoid cyclooxygenase pathway. Endocrinology 128:37–44PubMedGoogle Scholar
  28. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M (1988) Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 45:577–579PubMedGoogle Scholar
  29. Perucca E (2000) Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet 38:191–204PubMedCrossRefGoogle Scholar
  30. Pozzoli G, Tringali G, Dello Rusco C, Vairano M, Preziosi P, Navarra P (2001) HIV-1 Gp120 protein modulates corticotropin releasing factor synthesis and release via the stimulation of its mRNA from the rat hypothalamus in vitro: involvement of inducible nitric oxide synthase. J Neuroimmunol 118:268–276PubMedCrossRefGoogle Scholar
  31. Raadsheer FC, Hoogendijk WJ, Stam FC, Tilders FJ, Swaab DF (1994) Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 60:436–444PubMedCrossRefGoogle Scholar
  32. Sawchenko PE, Imaki T, Potter E, Kovacs K, Imaki J, Vale W (1993) The functional neuroanatomy of corticotropin-releasing factor. Ciba Found Symp 172:5–21PubMedGoogle Scholar
  33. Teoh H, Fowler LJ, Bowery NG (1995) Effect of lamotrigine on the electrically-evoked release of endogenous amino acids from slices of dorsal horn of the rat spinal cord. Neuropharmacology 34:1273–1278PubMedCrossRefGoogle Scholar
  34. Tringali G, Aubry JM, Moscianese K, Zamori C, Vairano M, Preziosi P, Navarra P, Pozzoli G (2004) Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission. J Psychiatry Neurosci 29:459–466PubMedGoogle Scholar
  35. Tsagarakis S, Navarra P, Rees LH, Besser GM, Grossman A (1989) Morphine directly modulates stimulated CRH-41 release from the rat hypothalamus in vitro. Endocrinology 124:2330–2335PubMedCrossRefGoogle Scholar
  36. Tsagarakis S, Rees LH, Besser GM, Grossman A (1991) Involvement of calmodulin in depolarization-induced release of corticotrophin-releasing hormone-41 from the rat hypothalamus in vitro. J Mol Endocrinol 7:71–75PubMedCrossRefGoogle Scholar
  37. von Wegerer J, Hesslinger B, Berger M, Walden J (1997) A calcium antagonistic effect of the new antiepileptic drug lamotrigine. Eur Neuropsychopharmacol 7:77–81CrossRefGoogle Scholar
  38. Wang SJ, Sihra TS, Gean PW (2001) Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity. NeuroReport 12:2255–2258PubMedCrossRefGoogle Scholar
  39. Xie X, Hagan RM (1998) Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology 38:119–130PubMedCrossRefGoogle Scholar
  40. Xie X, Lancaster B, Peakman T, Garthwaite J (1995) Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIA Na+ channels and with native zNa+ channels in rat hippocampal neurones. Pflugers Arch 430:437–446PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Giuseppe Tringali
    • 1
  • Jean Michel Aubry
    • 2
  • Pierluigi Navarra
    • 1
  • Giacomo Pozzoli
    • 1
  1. 1.Institute of PharmacologyCatholic University Medical SchoolRomeItaly
  2. 2.Department of PsychiatryHUGGenevaSwitzerland

Personalised recommendations